NEOSENS
- May 15, 2024
- 1 min read
Updated: Jan 30, 2025
 |
 |
 |
THE MISSION
Neosens addresses a global health concern, the unnecessary antibiotic treatment of 12% of all newborns in low- and middle-income countries (LMICs) due to sepsis suspicion. These overtreatments lead to serious adverse effects for newborns and place a significant financial burden on those countries. They also contribute to the alarming increase in antibiotic resistance, which is seen as a “global health and development threat” by the WHO. NEOSENS are developing a portable diagnostic device that combines the power of Machine Learning models with biomarker concentration measurements. Their device offers a solution that is not only fast and accurate but also highly cost-effective. Their customers will benefit from a 37% cost reduction per newborn tested.
THE TEAM
Karim Zahra (MSc) - CEO | Marco Fumagalli (MSc) - CTO | Mateo Hamel (MSc) - COO |
| | |
 |  |  |
SUSTAINABLE DEVELOPMENT GOALS
 |  |  |
GET INVOLVED
Are you intersted in learning more about NEOSENS? Get in touch with them here!
Comments